Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) (FRA:3D7) announced new scientific data related to the efficacy of its biosynthetically-derived cannabigerol (CBG) on human skin.
The company said that studies have demonstrated that Willow’s CBG is safe when applied to skin and eye areas, and can act as a more potent antioxidant and anti-inflammatory for other skin applications compared to plant-derived cannabidiol, or CBD.
In a statement, Willow told shareholders that its CBG demonstrated a “robust” safety profile, with no signs of skin or eye irritation, or phototoxicity.
READ: Willow Biosciences completes first commercial-scale fermentation run of ultra-pure CBG
A Human Repeat Insult Patch Test clinical trial was performed on more than 100 volunteers where Willow CBG was demonstrated to be safe for sensitive skin.
The results pave the way for the use of CBG in skincare, Willow said in a statement.
"Demonstrating the safety and benefit of a new ingredient like Willow's CBG is a critical step in commercialization and it's one that we take seriously at the company," said Chris Savile, Willow's COO.
"Willow's CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-microbial.”
Savile noted that Willow CBG was shown to be as potent or more potent than CBD – and, in some cases, up to twice as potent – in the performed assays.
“We believe the clinical work on human skin and in vitro models with CBG are the first of their kind to be reported and we are very excited to share the results with our stakeholders and industry."
Willow is a Canadian biotechnology company that produces high purity, plant-derived compounds for the global pharmaceutical, health and wellness, and consumer packaged goods industries. It has developed a proprietary biosynthetic process to manufacture CBG in commercial quantities.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas